NO20090469L - Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav - Google Patents

Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav

Info

Publication number
NO20090469L
NO20090469L NO20090469A NO20090469A NO20090469L NO 20090469 L NO20090469 L NO 20090469L NO 20090469 A NO20090469 A NO 20090469A NO 20090469 A NO20090469 A NO 20090469A NO 20090469 L NO20090469 L NO 20090469L
Authority
NO
Norway
Prior art keywords
activity
increase
compounds
substituted piperidines
hdm2 protein
Prior art date
Application number
NO20090469A
Other languages
English (en)
Inventor
Stephane L Bogen
Ronald J Doll
Latha G Nair
Zhuyan Guo
Yaolin Wang
Jr Gerald W Shipps
Yao Ma
Brian R Lahue
Matthew E Voss
Yuan Tian
Corey O Strickland
Rumin Zhang
Mark A Mccoy
Weidong Pan
Elise M Siegel
Craig R Gibeau
Original Assignee
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Res Inc filed Critical Albany Molecular Res Inc
Publication of NO20090469L publication Critical patent/NO20090469L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives forbindelser som er inhibitorer av HDM2-protein, fremgangsmåter for å fremstille slike forbindelser, farmasøytiske preparater som innbefatter én eller flere slike forbindelser, anvendelse ved behandling, forebyggelse eller inhibering av én eller flere sykdommer forbundet med HDM2-protein eller P53, ved å anvende slike forbindelser eller farmasøytiske preparater.
NO20090469A 2006-06-30 2009-01-29 Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav NO20090469L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81775306P 2006-06-30 2006-06-30
PCT/US2007/014958 WO2008005268A1 (en) 2006-06-30 2007-06-27 Substituted piperidines that increase p53 activity and the uses thereof

Publications (1)

Publication Number Publication Date
NO20090469L true NO20090469L (no) 2009-03-27

Family

ID=38656615

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090469A NO20090469L (no) 2006-06-30 2009-01-29 Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav

Country Status (17)

Country Link
US (1) US7884107B2 (no)
EP (1) EP2035416A1 (no)
JP (1) JP2009542666A (no)
KR (1) KR20090042779A (no)
CN (1) CN101595107A (no)
AR (1) AR061726A1 (no)
AU (1) AU2007269836A1 (no)
BR (1) BRPI0713119A2 (no)
CA (1) CA2656398A1 (no)
CO (1) CO6150158A2 (no)
IL (1) IL196152A0 (no)
MX (1) MX2009000285A (no)
NO (1) NO20090469L (no)
PE (1) PE20081238A1 (no)
TW (1) TW200808781A (no)
WO (1) WO2008005268A1 (no)
ZA (1) ZA200900204B (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
MX2008010635A (es) * 2006-02-16 2008-10-28 Schering Corp Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
CA2656393A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
AU2008265989B8 (en) 2007-06-15 2012-01-12 Microphage Incorporated Method of detection of microorganisms with enhanced bacteriophage amplification
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
WO2009105500A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
AR073578A1 (es) * 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
AU2009294673B2 (en) 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
BRPI0922572A2 (pt) 2008-12-17 2019-09-24 Scripps Research Inst método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
US8859776B2 (en) * 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
JP5984217B2 (ja) 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
WO2012018933A2 (en) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
MX2013006739A (es) * 2010-12-16 2013-07-17 Roche Glycart Ag Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
EP2720720B1 (en) 2011-06-14 2018-02-28 Yeda Research and Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
WO2013009825A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
EP2771008A4 (en) * 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES FOR INCREASING P53 ACTIVITY AND USES THEREOF
WO2013096150A1 (en) * 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
CA2862038C (en) * 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN102690826B (zh) * 2012-04-19 2014-03-05 山西医科大学 一种特异性降低人Aurora-A基因表达的shRNA及其应用
WO2014024993A1 (ja) * 2012-08-09 2014-02-13 国立大学法人京都大学 ピぺラジン誘導体およびその用途
US9603844B2 (en) * 2012-10-22 2017-03-28 Georgetown University Compositions and methods for treating mammary tumors
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
CN105358530A (zh) 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
PT3013833T (pt) 2013-06-26 2019-03-20 Univ Do Porto Oxazoloisoindolinonas derivadas de triptofanol: ativadoras de molécula pequena da p53
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
CA2956129C (en) 2014-08-21 2022-10-25 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN105597090B (zh) * 2014-11-14 2022-08-23 中国科学院上海营养与健康研究所 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
PL3359542T3 (pl) 2015-10-09 2021-09-20 Boehringer Ingelheim International Gmbh Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53
SG10202111851YA (en) 2015-10-16 2021-12-30 Fate Therapeutics Inc Platform for the Induction & Maintenance of Ground State Pluripotency
MX2018005274A (es) 2015-10-30 2019-09-19 The Regents Of The Universtiy Of California Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
CN109790116B (zh) 2016-09-20 2022-10-28 葛兰素史密斯克莱知识产权（第2 号）有限公司 Trpv4拮抗剂
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
EP4368200A3 (en) 2017-04-05 2024-07-17 Boehringer Ingelheim International GmbH Anticancer combination therapy
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
CN108864113B (zh) * 2018-08-03 2021-08-13 南方科技大学 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
CN110628735B (zh) * 2019-04-23 2022-04-08 天津科技大学 一种5α-还原酶突变体，基因工程菌及其在高效催化5α-AD生产中的应用
JP7740994B2 (ja) * 2019-06-10 2025-09-17 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療
EP4027994A4 (en) * 2019-09-13 2024-03-27 Dana-Farber Cancer Institute, Inc. KDM INHIBITORS AND THEIR USES
CN113633642A (zh) * 2021-08-26 2021-11-12 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) Abt-263在制备抑制角膜移植免疫排斥反应的药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09249566A (ja) 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
WO1998016527A1 (en) * 1996-10-15 1998-04-23 Fujisawa Pharmaceutical Co., Ltd. Benzoxepine derivatives which promote release of growth hormone
JP2000514838A (ja) * 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
EP0947494A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
PT1077941E (pt) * 1998-05-11 2010-07-01 Novo Nordisk As Compostos com propriedades de libertaã†o da hormona de crescimento
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
AR035312A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Compuestos de acido hidroxamico que contienen alquinilo como inhibidores de metaloproteinasa de matriz/tace, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
AU6690001A (en) * 2000-06-15 2001-12-24 Schering Corp Thrombin receptor antagonists
US6403584B1 (en) 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
US20020099035A1 (en) * 2001-01-24 2002-07-25 Sandanayaka Vincent P. Method for preparing alpha-sulfonyl hydroxamic acid derivatives
BR0215157A (pt) 2001-12-18 2004-10-19 Hoffmann La Roche Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores
CN1182113C (zh) * 2002-07-19 2004-12-29 中国科学院上海有机化学研究所 2，5－cis－二取代的吡咯烷衍生物、合成方法及其用途
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7632920B2 (en) 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
BRPI0511328A (pt) 2004-05-18 2007-12-04 Hoffmann La Roche cis-imidazolinas
HRP20110892T1 (hr) 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk

Also Published As

Publication number Publication date
CN101595107A (zh) 2009-12-02
KR20090042779A (ko) 2009-04-30
CO6150158A2 (es) 2010-04-20
BRPI0713119A2 (pt) 2012-04-17
MX2009000285A (es) 2009-06-08
WO2008005268A1 (en) 2008-01-10
CA2656398A1 (en) 2008-01-10
US7884107B2 (en) 2011-02-08
IL196152A0 (en) 2009-09-22
AR061726A1 (es) 2008-09-17
JP2009542666A (ja) 2009-12-03
PE20081238A1 (es) 2008-09-04
AU2007269836A1 (en) 2008-01-10
US20080004287A1 (en) 2008-01-03
EP2035416A1 (en) 2009-03-18
ZA200900204B (en) 2010-01-27
TW200808781A (en) 2008-02-16

Similar Documents

Publication Publication Date Title
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO20090628L (no) Pyridizinon derivativater
NO20092658L (no) New compounds
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20091605L (no) Pyridinonforbindelser
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
UA109417C2 (uk) ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
NO20084256L (no) DPP IV inhibitorformuleringer
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
NO20080785L (no) Behandling av kreft
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20081838L (no) 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application